GlassScriptPhysician profile
Marina Mathew
NPI 1285085886
$19,995.81
in general payments reported to CMS, 2019-2025
33 companies · $3,231 in 2025
The $3,231 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,931 · 2022: $4,757 · 2023: $3,603 · 2024: $4,474 · 2025: $3,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,080.33 |
| Education | $227.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,813.47 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,115.96 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,007.06 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,831.00 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,677.50 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $1,414.14 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $1,277.83 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,076.70 | 2021-2025 | Ingrezza |
| Corium, LLC | $745.88 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $651.44 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $532.36 | 2021-2025 | Sublocade, Perseris |
| Sunovion Pharmaceuticals INC. | $518.70 | 2021-2022 | |
| Axsome Therapeutics, INC. | $473.90 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $434.50 | 2021-2022 | |
| Eisai INC. | $401.82 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $401.48 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Almatica Pharma LLC | $299.93 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $299.56 | 2022-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $159.75 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.88 | 2024-2025 | Cobenfy |
| Tempus Ai, INC | $109.00 | 2024 | |
| Harmony Biosciences LLC | $108.82 | 2021-2023 | Wakix |
| Bausch Health US, LLC | $75.35 | 2021-2022 | |
| Neos Therapeutics, LP | $72.83 | 2023-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $68.42 | 2022-2025 | Qelbree |
| Adlon Therapeutics L.P. | $56.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $50.68 | 2023-2024 | Quviviq |
| Sage Therapeutics, LLC | $50.62 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.22 | 2025 | Rejoyn |
| Braeburn INC. | $31.96 | 2025 | Brixadi |
| Merck Sharp & Dohme LLC | $30.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.29 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.34 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.